Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics |
| |
Authors: | Erica L. Mayer Steven J. Isakoff Giannoula Klement Sean R. Downing Wendy Y. Chen Keri Hannagan Rebecca Gelman Eric P. Winer Harold J. Burstein |
| |
Affiliation: | 1. Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA 2. Brigham and Women??s Hospital, Harvard Medical School, Boston, MA, USA 3. Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA 4. Tufts University School of Medicine, Boston, MA, USA 5. Foundation Medicine, Cambridge, MA, USA
|
| |
Abstract: | This phase 1 study evaluated the safety and tolerability of antiangiogenic therapy using vandetanib and metronomic cyclophosphamide and methotrexate in metastatic breast cancer. Eligible patients had metastatic breast cancer with 0?C4 prior chemotherapy regimens. All received cyclophosphamide 50?mg daily, methotrexate 2.5?mg?days 1?C2?weekly, and vandetanib daily in 3 dose-escalation cohorts: 100?mg (C1), 200?mg (C2), and 300?mg (C3). The primary endpoint was safety and tolerability; secondary endpoints included response rate and evaluation of platelet-associated proteins. Twenty three patients were treated and evaluable for toxicity. Common mild toxicities included nausea, vomiting, LFTs abnormalities, fatigue, and rash. Three episodes of dose-limiting toxicity occurred in C3. In all cohorts, 1/3 of patients required vandetanib dose reduction, and 22?% ended therapy for toxicity. Of the 20 response-evaluable patients, 10?% demonstrated partial response and 15?% stable disease ??24?weeks. Proteomic analyses demonstrated changes in platelet content of angiogenesis regulators, including vascular endothelial growth factor and platelet factor 4, with exposure to therapy. This regimen was tolerable at a maximum vandetanib dose of 200?mg; modest clinical activity was observed in this heavily pretreated population. Changes in the platelet proteome may serve as pharmacodynamic markers of angiogenesis inhibition. Metronomic chemotherapy is an attractive partner with biologics and deserves further study in metastatic breast cancer. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|